loader image
Friday, June 6, 2025
97.9 F
McAllen
We Welcome your Press Release
- Advertisement -

Office Of The Governor Statement On COVID-19 Monoclonal Antibody Treatment

Translate to Spanish or other 102 languages!

overnor Abbott’s doctor prescribed Regeneron's monoclonal antibody therapy treatment, which is available at no cost to all Texans who get a doctor’s referral. Image for illustration purposes
Governor Abbott’s doctor prescribed Regeneron’s monoclonal antibody therapy treatment, which is available at no cost to all Texans who get a doctor’s referral. Image for illustration purposes

Mega Doctor News

- Advertisement -

AUSTIN – Office of the Governor Communications Director Mark Miner today issued the following statement:

“Governor Abbott’s doctor prescribed Regeneron’s monoclonal antibody therapy treatment, which is available at no cost to all Texans who get a doctor’s referral. It is recommended that Texans testing positive for COVID-19 seek this antibody therapeutic drug because of its effectiveness to help keep people out of hospitals. Today, the Governor announced the continued expansion of COVID-19 Antibody Infusion Centers across Texas. That is in addition to more than 140 providers that are providing antibody treatment at hospitals and clinics across the state.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Gerardo’s Story of Strength and Service

Mega Doctor News Mega Doctor News Diagnosed at just 4 months of age,...

DHR Health Orthopedic Sports Medicine Surgeon Dr. Daniel Romanelli completes 100th BEAR® implant

Mega Doctor News Orthopedic Sports Medicine Surgeon Dr. Daniel Romanelli completed his...

Leadership Evolution at UTRGV School of Medicine

Mega Doctor News By Roberto Hugo González Since its inception, the UTRGV School...

STHS McAllen: First Facility in the RGV with Innovative Procedure to Help Long-Term Dialysis Patients Regain Central Venous Access

Mega Doctor News A traditional treatment for patients experiencing significant kidney failure, dialysis aims...
- Advertisement -
×